DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2jkkx2/nucleic_acid) has announced the addition of the "Nucleic Acid Therapies in Oncology Drug Pipeline Update 2015" report to their offering.
Nucleic acid therapies in oncology includes: Gene Therapy, DNA vaccine, Other DNA technologies, RNA Interference (RNAi), Small interfering RNA (siRNA), Antisense RNA and Ribozymes.
There are today 238 companies plus partners developing 274 nucleic acid therapy drugs in 648 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 201 drugs.
Nucleic Acid Therapies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 210 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 179 out of the 179 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drug targets are further categorized in the software application by 60 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 3
- Pre-registration - 1
- Phase III - 14
- Phase II - 77
- Phase I - 81
- Preclinical - 188
- No Data - 6
- Suspended - 9
- Ceased - 201
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/2jkkx2/nucleic_acid
